down arrow

Scorpius Holdings, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US42237K4094
USD
0.01
0.00 (0.00%)

Dec 04

ASE

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.000.00

52 Week

0.000.80
Valuation
Technical
Day's Volume

CASH

3

Shareholding (Dec 2024)

FII

0.54%

Held by 5 FIIs

DII

98.99%

Held by 1 DIIs

Promoter

0.00%

How big is Scorpius Holdings, Inc.?

22-Jun-2025

As of Jun 18, Scorpius Holdings, Inc. has a market capitalization of 0.50 million, with net sales of 6.24 million and a net profit of -34.33 million over the last four quarters. The company has shareholder's funds of 6.30 million and total assets of 39.18 million as of Dec 24.

Market Cap: As of Jun 18, Scorpius Holdings, Inc. has a market capitalization of 0.50 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Scorpius Holdings, Inc. reported net sales of 6.24 million and a net profit of -34.33 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company has shareholder's funds of 6.30 million and total assets amounting to 39.18 million.

Read More

What does Scorpius Holdings, Inc. do?

22-Jun-2025

Scorpius Holdings, Inc. is a development-stage immuno-oncology company focused on creating allogeneic, off-the-shelf cellular therapeutic vaccines for cancer treatment. It has a market cap of $0.50 million, with recent net sales of $1 million and a net loss of $10 million.

Overview:<BR>Scorpius Holdings, Inc. is a development-stage immuno-oncology company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat various cancers, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1 Million (Quarterly Results - Dec 2024) <BR>Most recent Net Profit: -10 Million (Quarterly Results - Dec 2024) <BR>Market cap: USD 0.50 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 2.58 <BR>Return on Equity: -530.53% <BR>Price to Book: 0.08<BR><BR>Contact Details:<BR>Address: 627 DAVIS DRIVE, SUITE 400, MORRISVILLE NC : 27560 <BR>Tel: 1 919 2407133 <BR>Fax: 1 302 6365454 <BR>Website: http://www.heatbio.com/

Read More

Who are in the management team of Scorpius Holdings, Inc.?

22-Jun-2025

As of March 2022, the management team of Scorpius Holdings, Inc. includes Mr. Jeffrey Wolf as Chairman, President, and CEO, Dr. John Prendergast as Lead Independent Director, and Dr. John Monahan and Mr. Edward Smith as Independent Directors.

As of March 2022, the management team of Scorpius Holdings, Inc. includes Mr. Jeffrey Wolf, who serves as the Chairman of the Board, President, and Chief Executive Officer. Additionally, Dr. John Prendergast holds the position of Lead Independent Director, while Dr. John Monahan and Mr. Edward Smith serve as Independent Directors.

Read More

Is Scorpius Holdings, Inc. overvalued or undervalued?

20-Sep-2025

As of November 13, 2017, Scorpius Holdings, Inc. is classified as risky due to significant financial deterioration, overvaluation indicated by a Price to Book Value of 0.08, an EV to EBITDA of -0.65, a Return on Equity of -530.53%, and a year-to-date stock return of -99.61% compared to the S&P 500's 12.22%.

As of 13 November 2017, the valuation grade for Scorpius Holdings, Inc. moved from does not qualify to risky, indicating a significant deterioration in its financial standing. The company appears to be overvalued given its negative performance metrics, including a Price to Book Value of 0.08, an EV to EBITDA of -0.65, and a Return on Equity (ROE) of -530.53%. <BR><BR>In comparison to its peers, Scorpius Holdings has a less favorable EV to EBITDA ratio than Lisata Therapeutics, Inc. at 0.1349 and Lipocine, Inc. at 0.3892, both of which are also classified as risky. The company's stock has dramatically underperformed against the S&P 500, with a year-to-date return of -99.61% compared to the index's 12.22%, reinforcing the notion that it is overvalued in the current market context.

Read More

Is Scorpius Holdings, Inc. technically bullish or bearish?

20-Sep-2025

As of May 8, 2025, Scorpius Holdings, Inc. shows a mildly bearish trend overall, with conflicting signals from technical indicators, including a bearish daily moving average and a year-to-date return of -99.61% compared to the S&P 500's 12.22%.

As of 8 May 2025, the technical trend for Scorpius Holdings, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish overall, driven by a bearish daily moving average and a bearish weekly KST. The MACD shows mildly bullish signals on both weekly and monthly time frames, while the RSI indicates a bearish weekly but bullish monthly trend. Bollinger Bands are sideways weekly and mildly bearish monthly. The stock has significantly underperformed against the S&P 500, with a year-to-date return of -99.61% compared to the S&P 500's 12.22%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 0 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-10.43

stock-summary
Return on Equity

2,699.73%

stock-summary
Price to Book

-0.09

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Mar 2025)
Net Profit:
-11 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
210.34%
0%
210.34%
6 Months
-77.5%
0%
-77.5%
1 Year
-98.09%
0%
-98.09%
2 Years
-99.99%
0%
-99.99%
3 Years
-99.3%
0%
-99.3%
4 Years
-100.0%
0%
-100.0%
5 Years
-100.0%
0%
-100.0%

Scorpius Holdings, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Scorpius Holdings, Inc. technically bullish or bearish?

As of 8 May 2025, the technical trend for Scorpius Holdings, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish overall, driven by a bearish daily moving average and a bearish weekly KST. The MACD shows mildly bullish signals on both weekly and monthly time frames, while the RSI indicates a bearish weekly but bullish monthly trend. Bollinger Bands are sideways weekly and mildly bearish monthly. The stock has significantly underperformed against the S&P 500, with a year-to-date return of -99.61% compared to the S&P 500's 12.22%....

Read More

Is Scorpius Holdings, Inc. overvalued or undervalued?

As of 13 November 2017, the valuation grade for Scorpius Holdings, Inc. moved from does not qualify to risky, indicating a significant deterioration in its financial standing. The company appears to be overvalued given its negative performance metrics, including a Price to Book Value of 0.08, an EV to EBITDA of -0.65, and a Return on Equity (ROE) of -530.53%. In comparison to its peers, Scorpius Holdings has a less favorable EV to EBITDA ratio than Lisata Therapeutics, Inc. at 0.1349 and Lipocine, Inc. at 0.3892, both of which are also classified as risky. The company's stock has dramatically underperformed against the S&P 500, with a year-to-date return of -99.61% compared to the index's 12.22%, reinforcing the notion that it is overvalued in the current market context....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-1.98%
EBIT Growth (5y)
-28.10%
EBIT to Interest (avg)
-36.21
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
2.58
Sales to Capital Employed (avg)
0.21
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
12.27%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.08
EV to EBIT
-0.51
EV to EBITDA
-0.65
EV to Capital Employed
0.74
EV to Sales
2.69
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-145.54%
ROE (Latest)
-530.53%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bullish
Bullish
Bollinger Bands
Sideways
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 4 Schemes (0.46%)

Foreign Institutions

Held by 5 Foreign Institutions (0.54%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is -80.00% vs 11.11% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is -15.31% vs 6.67% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.20",
          "val2": "1.00",
          "chgp": "-80.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.70",
          "val2": "-6.20",
          "chgp": "8.06%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.20",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.20",
          "val2": "-1.40",
          "chgp": "-57.14%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.30",
          "val2": "-9.80",
          "chgp": "-15.31%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-34,549.90%",
          "val2": "-7,619.70%",
          "chgp": "-2,693.02%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -11.43% vs 1,650.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 17.94% vs -0.97% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "6.20",
          "val2": "7.00",
          "chgp": "-11.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-25.70",
          "val2": "-35.60",
          "chgp": "27.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.00",
          "val2": "0.80",
          "chgp": "25.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.90",
          "val2": "0.10",
          "chgp": "-1,000.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-34.30",
          "val2": "-41.80",
          "chgp": "17.94%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-5,262.00%",
          "val2": "-6,009.00%",
          "chgp": "74.70%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQstock-summary
Mar'25
Dec'24
Change(%)
Net Sales
0.20
1.00
-80.00%
Operating Profit (PBDIT) excl Other Income
-5.70
-6.20
8.06%
Interest
0.20
0.20
Exceptional Items
-2.20
-1.40
-57.14%
Consolidate Net Profit
-11.30
-9.80
-15.31%
Operating Profit Margin (Excl OI)
-34,549.90%
-7,619.70%
-2,693.02%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Mar 2025 is -80.00% vs 11.11% in Dec 2024

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Mar 2025 is -15.31% vs 6.67% in Dec 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
6.20
7.00
-11.43%
Operating Profit (PBDIT) excl Other Income
-25.70
-35.60
27.81%
Interest
1.00
0.80
25.00%
Exceptional Items
-0.90
0.10
-1,000.00%
Consolidate Net Profit
-34.30
-41.80
17.94%
Operating Profit Margin (Excl OI)
-5,262.00%
-6,009.00%
74.70%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -11.43% vs 1,650.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 17.94% vs -0.97% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Scorpius Holdings, Inc. stock-summary
stock-summary
Scorpius Holdings, Inc.
Pharmaceuticals & Biotechnology
Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.
Company Coordinates stock-summary
Company Details
627 DAVIS DRIVE, SUITE 400 , MORRISVILLE NC : 27560
stock-summary
Tel: 1 919 2407133
stock-summary
http://www.heatbio.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."